Inmune Bio (INMB) EPS (Basic) (2018 - 2026)

Inmune Bio (INMB) posted EPS (Basic) of -$0.23 for Q1 2026, up 6.07% sequentially from -$0.24 in Q4 2025, and up 73.35% YoY from -$0.13 in Q1 2025.

Inmune Bio (INMB) EPS (Basic) (2018 - 2026) Analysis & Trends

Inmune Bio has reported EPS (Basic) for 9 years, with the latest figure at -$0.23 in Q1 2026.

Quarterly EPS (Basic) rose 73.35% year-over-year to -$0.23 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.71 (up 81.47% YoY) and the FY2025 annual result came in at -$3.32, up 3.21% from the prior year.
EPS (Basic) climbed to -$0.23 in Q1 2026 per INMB's latest filing, from -$0.24 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.23 in Q1 2026 and troughed at -$29.67 in Q3 2022.
A 5-year average of -$2.76 and a median of -$0.52 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2024: EPS (Basic) soared 97.49% in 2023, then sank 945.68% in 2024.
Over 5 years, EPS (Basic) stood at -$0.36 in 2022, then slumped by 42.11% to -$0.52 in 2023, then declined by 2.16% to -$0.53 in 2024, then soared by 53.8% to -$0.24 in 2025, then grew by 6.07% to -$0.23 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.23, -$0.24, and -$0.32 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Inmune Bio	58.11 Mn	39.70 Mn	-	-0.06

Download Data